A meta-analysis of adoptive immunotherapy in postoperative hepatocellular carcinoma

Abstract

This review provides available evidences that AIT, especially the treatment of LAK, can be used to decrease the early recurrence and mortality of postoperative HCC but may not the long term.

Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?

“…In particular, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group after 5 years of follow-up, with significantly reduced risk of recurrence (HR: 0.67; 95% CI: 0.48-0.94) and death from all causes (HR: 0.33; 95% CI: 0.15-0.76) for both. Overall, all the meta-analyses available to date [80][81][82] agree in confirming the efficacy of adjuvant AIT in increasing both RFS and OS significantly. However, this benefit appears to be time-dependent as it lasts only the first 3 [80,82] or 5 years [81] after treatment.…”

“…Overall, all the meta-analyses available to date [80][81][82] agree in confirming the efficacy of adjuvant AIT in increasing both RFS and OS significantly. However, this benefit appears to be time-dependent as it lasts only the first 3 [80,82] or 5 years [81] after treatment. AIT would, in fact, be able to effectively counteract the occult intra-or extrahepatic neoplastic dissemination responsible for early recurrences but would not affect the carcinogenic substrate determined by cirrhosis, which is the cause of de novo tumorigenesis and late recurrence, instead [27].…”